NCT07029139

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

A Multicenter, Randomized, Controlled, Open-label Phase II Clinical Study Evaluating the Efficacy and Safety of JMT601 Injection in Participants With Primary Membranous Nephropathy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 156 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy. The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	JMT601 Injection	In accordance with the protocol
DRUG	Rituximab	In accordance with the protocol
DRUG	Cyclosporin Capsules	In accordance with the protocol

Timeline

• Start date: 2025-06-30
• Primary completion: 2027-04-01
• Completion: 2029-03-01
• First posted: 2025-06-19
• Last updated: 2025-06-19